Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (Nasdaq: CDNA) announced the acquisition of TX Services, LLC, including its TX Connect service, which adds 19,000 patient referrals for kidney transplants. This cloud-based service allows nephrologists and dialysis centers to streamline electronic referrals to transplant programs. The integration enhances CareDx's pre-transplant offerings, complementing existing services like XynManagement. CEO Reg Seeto highlighted that TX Connect aids in helping more kidney patients get on transplant waitlists, enhancing patient care through better communication and management across the healthcare continuum.
CareDx, a precision medicine company, reported strong financial results for Q4 and full-year 2020. Q4 revenue reached $58.6 million, a 64% increase year-over-year, contributing to a record $192.2 million for the full year, up 51% from 2019. The company achieved a non-GAAP net income of $4.3 million in Q4 and $11.3 million for the full year. Despite a GAAP net loss of $3.5 million in Q4, the results signal a positive trajectory. Additionally, CareDx has provided over 79,000 patient results in 2020 and received Medicare reimbursement for AlloSure Heart.
CareDx, Inc. (Nasdaq: CDNA) is set to showcase its AlloSure donor-derived cell-free DNA (dd-cfDNA) technology at the Cutting Edge of Transplantation Meeting, occurring from February 25-27, 2021. Key presentations will include the ADMIRAL study, highlighting AlloSure's effectiveness in detecting allograft rejection among over 1,000 patients across various transplant centers. Additional research will be presented on the clinical applications of dd-cfDNA in real-life settings, including case studies and its relevance during the COVID-19 pandemic. CEO Reg Seeto emphasized the significance of these findings for post-transplant patient care.
CareDx, Inc. (CDNA) will release its financial results for the fourth quarter and full year 2020 after market close on February 24, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, with dial-in numbers available for domestic and international callers. CareDx is renowned for its precision medicine solutions for transplant patients, offering testing services and digital healthcare solutions.
CareDx, Inc. (Nasdaq: CDNA) announced that underwriters for its public stock offering exercised their option to purchase 288,461 additional shares at $91.00 each, generating approximately $24.7 million in net proceeds. This follows the initial offering of 1,923,077 shares, closing on January 25, 2021. The total number of shares sold in this public offering is 2,211,538, resulting in net proceeds of around $188.7 million after expenses. Goldman Sachs and Jefferies served as joint book-running managers for the offering.
CareDx, a leader in precision medicine, has announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. This event will take place on February 18, 2021, at 3:30 PM EST, where the company's management will present insights about their high-value healthcare solutions for transplant patients.
Investors can tune in to the live and archived webcast through CareDx's investor relations site. The company is dedicated to developing testing services and digital healthcare solutions for transplant patients.
CareDx has announced its participation at the 2021 Transplantation and Cellular Therapy (TCT) meeting, taking place from February 8-12, 2021. The company will present four abstracts, including a collaboration with Atara Biotherapeutics on the AlloCell therapeutic. This research focuses on pharmacokinetic assessment in clinical trials. CareDx will also feature AlloHeme and AlloSeq HCT for monitoring stem cell transplant patients. Senior executives express enthusiasm for advancing cellular transplantation solutions, emphasizing the importance of their data in transforming cell therapies.
CareDx, a precision medicine company, announced the closing of its public offering of 1,923,077 shares at $91.00 each, raising approximately $164 million in net proceeds. This offering allows CareDx to strengthen its working capital and support general corporate purposes. Additionally, underwriters have a 30-day option to purchase 288,461 more shares. The company's shares are traded under the symbol CDNA.
CareDx, Inc. (Nasdaq: CDNA) has announced a public offering of 1,923,077 shares at $91.00 each, aiming for gross proceeds of $175 million. The offering, closing around January 25, 2021, includes a 30-day option for underwriters to purchase an additional 288,461 shares. Funds from the offering will be directed towards working capital and corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC lead the offering as joint book-running managers. The offering is registered under a shelf registration statement filed with the SEC.
CareDx, Inc. (Nasdaq: CDNA) announced plans to offer and sell $175.0 million of its common stock in a public offering, with a potential additional $26.25 million from underwriters' options. The funds will be allocated for working capital and general corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC are the joint book-running managers for this offering, which is subject to market conditions and regulatory approval. CareDx's common stock is traded under the ticker symbol CDNA.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
